New York State Common Retirement Fund Lowers Stock Position in Johnson & Johnson $JNJ

29 Nov 2025, 13:38 by Tristan Rich · The Markets Daily

New York State Common Retirement Fund trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,152,765 shares of the company’s stock after selling 39,404 shares during the quarter. Johnson & Johnson makes up approximately 0.6% of New York State Common Retirement Fund’s investment portfolio, making the stock its 20th biggest holding. New York State Common Retirement Fund owned about 0.13% of Johnson & Johnson worth $481,585,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. GFG Capital LLC bought a new stake in Johnson & Johnson during the second quarter valued at about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $48,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. Finally, Vermillion & White Wealth Management Group LLC raised its stake in shares of Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.3%

NYSE:JNJ opened at $206.89 on Friday. The company has a market capitalization of $498.46 billion, a P/E ratio of 19.97, a PEG ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $207.81. The firm has a fifty day simple moving average of $191.33 and a 200-day simple moving average of $173.36.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a report on Monday, October 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Raymond James Financial upped their target price on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $201.05.

View Our Latest Report on JNJ

Johnson & Johnson Profile

(Free Report)